Outcomes of octogenarians and nonagenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study.
Bacteremia
Octogenarian
Outcomes
Pseudomonas
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
05
10
2022
accepted:
19
12
2022
medline:
19
7
2023
pubmed:
27
12
2022
entrez:
26
12
2022
Statut:
ppublish
Résumé
P. aeruginosa bacteremia is a common and severe infection carrying high mortality in older adults. We aimed to evaluate outcomes of P. aeruginosa bacteremia among old adults (≥ 80 years). We included the 464/2394 (19%) older adults from a retrospective multinational (9 countries, 25 centers) cohort study of individuals hospitalized with P. aeruginosa bacteremia. Bivariate and multivariable logistic regression models were used to evaluate risk factors for 30-day mortality among older adults. Among 464 adults aged ≥ 80 years, the mean age was 84.61 (SD 3.98) years, and 274 (59%) were men. Compared to younger patients, ≥ 80 years adults had lower Charlson score; were less likely to have nosocomial acquisition; and more likely to have urinary source. Thirty-day mortality was 30%, versus 27% among patients 65-79 years (n = 894) and 25% among patients < 65 years (n = 1036). Multivariate analysis for predictors of mortality among patients ≥ 80 years, demonstrated higher SOFA score (odds ratio [OR] 1.36, 95% confidence interval [CI] 1.23-1.51, p < 0.001), corticosteroid therapy (OR 3.15, 95% CI: 1.24-8.01, p = 0.016) and hospital acquired P. aeruginosa bacteremia (OR 2.30, 95% CI: 1.33-3.98, p = 0.003) as predictors. Appropriate empirical therapy within 24 h, type of definitive anti-pseudomonal drug, and type of regimen (monotherapy or combination) were not associated with 30-day mortality. In older adults with P. aeruginosa bacteremia, background conditions, place of acquisition, and disease severity are associated with mortality, rather than the antimicrobial regimen. In this regard, preventive efforts and early diagnosis before organ failure develops might be beneficial for improving outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
P. aeruginosa bacteremia is a common and severe infection carrying high mortality in older adults. We aimed to evaluate outcomes of P. aeruginosa bacteremia among old adults (≥ 80 years).
METHODS
METHODS
We included the 464/2394 (19%) older adults from a retrospective multinational (9 countries, 25 centers) cohort study of individuals hospitalized with P. aeruginosa bacteremia. Bivariate and multivariable logistic regression models were used to evaluate risk factors for 30-day mortality among older adults.
RESULTS
RESULTS
Among 464 adults aged ≥ 80 years, the mean age was 84.61 (SD 3.98) years, and 274 (59%) were men. Compared to younger patients, ≥ 80 years adults had lower Charlson score; were less likely to have nosocomial acquisition; and more likely to have urinary source. Thirty-day mortality was 30%, versus 27% among patients 65-79 years (n = 894) and 25% among patients < 65 years (n = 1036). Multivariate analysis for predictors of mortality among patients ≥ 80 years, demonstrated higher SOFA score (odds ratio [OR] 1.36, 95% confidence interval [CI] 1.23-1.51, p < 0.001), corticosteroid therapy (OR 3.15, 95% CI: 1.24-8.01, p = 0.016) and hospital acquired P. aeruginosa bacteremia (OR 2.30, 95% CI: 1.33-3.98, p = 0.003) as predictors. Appropriate empirical therapy within 24 h, type of definitive anti-pseudomonal drug, and type of regimen (monotherapy or combination) were not associated with 30-day mortality.
CONCLUSIONS
CONCLUSIONS
In older adults with P. aeruginosa bacteremia, background conditions, place of acquisition, and disease severity are associated with mortality, rather than the antimicrobial regimen. In this regard, preventive efforts and early diagnosis before organ failure develops might be beneficial for improving outcomes.
Identifiants
pubmed: 36571672
doi: 10.1007/s15010-022-01973-x
pii: 10.1007/s15010-022-01973-x
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1003-1012Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Gransden WR, Eykyn SJ, Phillips I. Septicaemia in the newborn and elderly. J Antimicrob Chemother. 1994;34:101–19.
doi: 10.1093/jac/34.suppl_A.101
pubmed: 7844066
Meyers BR, Sherman E, Mendelson MH, et al. Bloodstream infections in the elderly. Am J Med. 1989;86:379–84.
doi: 10.1016/0002-9343(89)90333-1
pubmed: 2929625
Muder RR, Brennen C, Wagener MM, Goetz AM. Bacteremia in a long-term-care facility: a five-year prospective study of 163 consecutive episodes. Clin Infect Dis. 1992;14:647–54.
doi: 10.1093/clinids/14.3.647
pubmed: 1562655
Rudman D, Hontanosas A, Cohen Z, Mattson DE. Clinical correlates of bacteremia in a Veterans Administration extended care facility. J Am Geriatr Soc. 1988;36:726–32.
doi: 10.1111/j.1532-5415.1988.tb07175.x
pubmed: 3042843
Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003;37:745–51.
doi: 10.1086/377200
pubmed: 12955633
Horino T, Chiba A, Kawano S, Kato T, Sato F, Maruyama Y, et al. Clinical characteristics and risk factors for mortality in patients with bacteremia caused by Pseudomonas aeruginosa. Intern Med. 2012;51:59–64.
doi: 10.2169/internalmedicine.51.5698
pubmed: 22214624
Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–17.
doi: 10.1086/421946
pubmed: 15306996
Leibovici L, Samra Z, Konigsberger H, Drucker M, Ashkenazi S, Pitlik SD. Long-term survival following bacteremia or fungemia. JAMA. 1995;274:807–12.
doi: 10.1001/jama.1995.03530100047033
pubmed: 7650804
Ammerlaan HS, Harbarth S, Buiting AG, Crook DW, Fitzpatrick F, Hanberger H, et al. Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. Clin Infect Dis. 2013;56:798–805.
doi: 10.1093/cid/cis1006
pubmed: 23223600
Aliaga L, Mediavilla JD, Cobo F. A clinical index predicting mortality with Pseudomonas aeruginosa bacteraemia. J Med Microbiol. 2002;51:615–701.
doi: 10.1099/0022-1317-51-7-615
pubmed: 12132781
Lee CC, Lee CH, Hong MY. Risk factors and outcome of Pseudomonas aeruginosa bacteremia among adults visiting the ED. Am J Emerg Med. 2012;30:852–60.
doi: 10.1016/j.ajem.2011.05.029
pubmed: 21855263
Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005;49:1306–11.
doi: 10.1128/AAC.49.4.1306-1311.2005
pubmed: 15793102
pmcid: 1068618
Vidal F, Mensa J, Almela M, Martínez JA, Marco F, Casals C, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med. 1996;156:2121–6.
doi: 10.1001/archinte.1996.00440170139015
pubmed: 8862105
Cheong HS, Kang CI, Wi YM, Ko KS, Chung DR, Lee NY, et al. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia. Eur J Clin Microbiol Infect Dis. 2008;27:1219–25.
doi: 10.1007/s10096-008-0568-5
pubmed: 18575908
Joo EJ, Kang CI, Ha YE, Kang SJ, Park SY, Chung DR, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb Drug Resist. 2011;17:305–12.
doi: 10.1089/mdr.2010.0170
pubmed: 21381966
Kim YJ, Jun YH, Kim YR, Park KG, Park YJ, Kang JY, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy. BMC Infect Dis. 2014;14:161.
doi: 10.1186/1471-2334-14-161
pubmed: 24655422
pmcid: 3994322
Schechner V, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, et al. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy. Diagn Microbiol Infect Dis. 2011;71:38–45.
doi: 10.1016/j.diagmicrobio.2011.05.010
pubmed: 21763093
Su TY, Ye JJ, Hsu PC, Wu HF, Chia JH, Lee MH. Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia. J Microbiol Immunol Infect. 2015;48:175–82.
doi: 10.1016/j.jmii.2013.07.009
pubmed: 24064286
Girard TD, Ely EW. Bacteremia and sepsis in older adults. Clin Geriatr Med. 2007;23:633–47. https://doi.org/10.1016/j.cger.2007.05.003 .
doi: 10.1016/j.cger.2007.05.003
pubmed: 17631238
Richardson JP. Bacteremia in the elderly. J Gen Intern Med. 1993;8:89–92.
doi: 10.1007/BF02599992
pubmed: 8441082
Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, et al. Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection: a multisite retrospective study. Clin Infect Dis. 2020;70:2270–80.
doi: 10.1093/cid/ciz668
pubmed: 31323088
Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, et al. Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study. J Antimicrob Chemother. 2021;76:2172–81.
doi: 10.1093/jac/dkab134
pubmed: 33993273
Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:762–74.
doi: 10.1001/jama.2016.0288
pubmed: 26903335
pmcid: 5433435
Tschudin-Sutter S, Fosse N, Frei R, Widmer AF. Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections. PLoS ONE. 2018;3:e0203295.
doi: 10.1371/journal.pone.0203295
Shi Q, Huang C, Xiao T, et al. A retrospective analysis of Pseudomonas aeruginosa bloodstreaminfections: prevalence, risk factors, and outcome in carbapenem- susceptible and -non-susceptible infections. Antimicrob Resist Infect Control. 2019;8:68.
doi: 10.1186/s13756-019-0520-8
pubmed: 31057792
pmcid: 6485151
Pena C, Suarez C, Ocampo-Sosa A, et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa blood stream infections: a post hoc analysis of a prospective cohort. Clin Infect Dis. 2013;57:208–16.
doi: 10.1093/cid/cit223
pubmed: 23580739
Obodozie-Ofoegbu OO, Teng C, Mortensen EM, Frei CR. Antipseudomonal monotherapy or combination therapy for older adults with community-onset pneumonia and multidrug-resistant risk factors: a retrospective cohort study. Am J Infect Control. 2019;47:1053–8.
doi: 10.1016/j.ajic.2019.02.018
pubmed: 30904374
pmcid: 6710104
Garrouste-Orgeas M, Timsit JF, Tafflet M, et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis. 2006;42:1118–26.
doi: 10.1086/500318
pubmed: 16575729
Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 1998;244:379–86.
doi: 10.1046/j.1365-2796.1998.00379.x
pubmed: 9845853
Osih RB, McGregor JC, Rich SE, Moore AC, Furuno JP, Perencevich EN, et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2007;51:839–44.
doi: 10.1128/AAC.00901-06
pubmed: 17194829
Lin MY, Weinstein RA, Hota B. Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother. 2008;52:3188–94.
doi: 10.1128/AAC.01553-07
pubmed: 18625778
pmcid: 2533498
Babich T, Zusman O, Elbaz M, Ben-Zvi H, Paul M, Leibovici L, Avni T. Empirical antibiotic treatment does not improve outcomes in catheter-associated urinary tract infection: prospective cohort study. Clin Infect Dis. 2017;65:1799–805.
doi: 10.1093/cid/cix680
pubmed: 29020203
Schuttevaer R, Alsma J, Brink A, van Dijk W, de Steenwinkel JEM, Lingsma HF, et al. Appropriate empirical antibiotic therapy and mortality: conflicting data explained by residual confounding. PLoS ONE. 2019;14: e0225478.
doi: 10.1371/journal.pone.0225478
pubmed: 31743361
pmcid: 6863559
Migiyama Y, Yanagihara K, Kaku N, Harada Y, Yamada K, Nagaoka K, et al. Pseudomonas aeruginosa bacteremia among immunocompetent and immunocompromised patients: relation to initial antibiotic therapy and survival. Jpn J Infect Dis. 2016;69:91–6.
doi: 10.7883/yoken.JJID.2014.573
pubmed: 26073727
Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, Pilcher DV, Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcomes and Resource Evaluation (CORE). Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017;317:290–300.
doi: 10.1001/jama.2016.20328
pubmed: 28114553
Thomas TP. The complications of systemic corticosteroid therapy in the elderly. A retrospective study. Gerontology. 1984;30:60–5.
doi: 10.1159/000212608
pubmed: 6698408
Goldwasser P, Feldman J. Association of serum albumin and mortality risk. J Clin Epidemiol. 1997;50:693–703. https://doi.org/10.1016/s0895-4356(97)00015-2 .
doi: 10.1016/s0895-4356(97)00015-2
pubmed: 9250267
Arnau-Barrés I, Güerri-Fernández R, Luque S, Sorli L, Vázquez O, Miralles R. Serum albumin is a strong predictor of sepsis outcome in elderly patients. Eur J Clin Microbiol Infect Dis. 2019;38:743–6.
doi: 10.1007/s10096-019-03478-2
pubmed: 30680575
Saedi AA, Feehan J, Phu S, Duque G. Current and emerging biomarkers of frailty in the elderly. Clin Interv Aging. 2019;19:389–98.
doi: 10.2147/CIA.S168687
Joseph JT, Roy SS, Shams N, Visintainer P, Wormser GP. A Collaborative approach intended to reduce the duration of short term urinary catheters in adult patients at a tertiary care medical center also significantly reduced the duration of hospitalization. Am J Infect Control. 2021;50:954–9.
doi: 10.1016/j.ajic.2021.11.032
pubmed: 34896198